Overview

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy

Status:
Terminated

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period. The primary purpose of the study is to demonstrate the efficacy and safety of ofatumumab in reducing clinical signs and symptoms in adult RA patients who had an inadequate response to TNF-α antagonist therapy.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Ofatumumab